Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Cited by (1,034)

Items 401–500 of 1,034

1. Integrated single-cell analysis revealed immune dynamics during Ad5-nCoV immunization
   Qi-Qi Cao, Shi-Po Wu, Chuan-Le Xiao, Shu-Zhen Chen, Xiang-Yang Chi, Xiuliang Cui, Hao Tang, Wen-Ru Su, Ying-Feng Zheng, Jia-Yong Zhong et al. · 2021 · Cell Discovery
2. Structure-based design of a highly stable, covalently-linked SARS-CoV-2 spike trimer with improved structural properties and immunogenicity
   Eduardo Olmedillas, Colin J. Mann, Wei-Wei Peng, Ying-Ting Wang, Ruben Diaz Avalos, Daniel H. Bedinger, Kristen M. Valentine, N. Shafee, S. Schendel, M. Yuan et al. · 2021 · bioRxiv
3. Characterisation of B.1.1.7 and Pangolin coronavirus spike provides insights on the evolutionary trajectory of SARS-CoV-2
   Samuel J. Dicken, Matthew J Murray, Lucy Thorne, Ann‐Kathrin Reuschl, Calum Forrest, Maaroothen Ganeshalingham, Luke Muir, Mphatso D. Kalemera, Machaela Palor, Laura E. McCoy et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
4. The role and uses of antibodies in COVID-19 infections: a living review
   David Oliver Scourfield, Sophie G. Reed, Max N. Quastel, Jennifer Alderson, Valentina M T Bart, Alicia Teijeira Crespo, Ruth E. Jones, Ellie Pring, Felix Clemens Richter, David Ahern et al. · 2021 · Oxford Open Immunology
5. Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection
   Jamie Guenthoer, Michelle Lilly, Tyler N. Starr, Bernadeta Dadonaite, Klaus N. Lovendahl, Jacob T. Croft, Caitlin I. Stoddard, Vrasha Chohan, Shilei Ding, Felicitas Ruiz et al. · 2023 · Proceedings of the National Academy of Sciences
6. Structural basis of Omicron neutralization by affinity-matured public antibodies
   D. Sheward, Pradeepa Pushparaj, H. Das, Changil Kim, Sungyong Kim, L. Hanke, R. Dyrdak, G. Mcinerney, J. Albert, B. Murrell et al. · 2022 · bioRxiv
7. Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern
   A. Gorchakov, S. Kulemzin, S. Guselnikov, K. Baranov, T. N. Belovezhets, L. Mechetina, O. Volkova, A. Najakshin, N. Chikaev, A. Chikaev et al. · 2021 · Cell Discovery
8. Animal models of SARS-CoV-2 transmission
   R. D. de Vries, B. Rockx, B. Haagmans, S. Herfst, M. Koopmans, R. D. de Swart · 2021 · Current Opinion in Virology
9. Antibodies Responses to SARS-CoV-2 in a Large Cohort of Vaccinated Subjects and Seropositive Patients
   Emanuele Amodio, Giuseppina Capra, Alessandra Casuccio, Simona De Grazia, Dario Genovese, Stefano Pizzo, Giuseppe Calamusa, Donatella Ferraro, Anna Giammanco, Francesco Maria Vitale et al. · 2021 · Vaccines
10. Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2
    Xiaojuan Zhou, Fengge Ma, Jun Xie, M. Yuan, Yunqiao Li, N. Shaabani, Fang-Zhu Zhao, De-Li Huang, Nicholas C. Wu, C. D. Lee et al. · 2021 · Cell Reports
11. Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection
    Mingxi Li, Jingao Guo, Shuai-Yao Lu, Run-Hong Zhou, Hong-Yan Shi, Xuan-Ling Shi, Lin Cheng, Qing Liang, Hong-Qi Liu, Pui Wang et al. · 2021 · Frontiers in Immunology
12. Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
    Ligong Lu, Hui Zhang, Meixiao Zhan, Jun Jiang, Hua Yin, Danielle J. Dauphars, Shi-You Li, Yong Li, You-Wen He · 2020 · Science China Life Sciences
13. Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity
    J. Jensen, R. Sankhala, V. Dussupt, Hong-Jun Bai, A. Hajduczki, Kerri G. Lal, William C. Chang, E. Martinez, Caroline E. Peterson, Emily Golub et al. · 2023 · Journal of Virology
14. A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants
    Novalia Pishesha, Thibault J. Harmand, Paul W. Rothlauf, Patrique Praest, Ryan Alexander, Renate van den Doel, Mariel J. Liebeskind, Maria A. Vakaki, Nicholas McCaul, Charlotte Wijne et al. · 2021 · Proceedings of the National Academy of Sciences
15. The fatty acid site is coupled to functional motifs in the SARS-CoV-2 spike protein and modulates spike allosteric behaviour
    A. S. Oliveira, D. Shoemark, Amaurys Avila Ibarra, A. Davidson, I. Berger, C. Schaffitzel, A. Mulholland · 2021 · bioRxiv
16. Therapeutic Potential of Exploiting Autophagy Cascade Against Coronavirus Infection
    Subhajit Maity, A. Saha · 2021 · Frontiers in Microbiology
17. Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike
    Graham, Carl, Seow, Jeffrey, Huettner, Isabella, Khan, Hataf, Kouphou, Neophytos, Acors, Sam, Winstone, Helena, Pickering, Suzanne, Galao, Rui Pedro, Lista, Maria Jose et al. · 2021
18. Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection
    K. M. Konrath, K. Liaw, Yuan-Han Wu, Xi-Zhou Zhu, Susanne N. Walker, Ziyang Xu, K. Schultheis, Neethu Chokkalingam, H. Chawla, Jianqiu Du et al. · 2022 · Cell Reports
19. Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats
    Johnstone Tcheou, Ariel J. Raskin, Gagandeep Singh, Hisaaki Kawabata, Dominika A. Bielak, Weina Sun, Irene González‐Domínguez, D. Noah Sather, Adolfo García‐Sastre, Peter Palese et al. · 2021 · Frontiers in Immunology
20. Progression and Resolution of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Golden Syrian Hamsters
    Kathleen R. Mulka, S. Beck, Clarisse V. Solis, Andrew L. Johanson, S. Queen, Megan E. McCarron, M. Richardson, R. Zhou, Paula Marinho, Anne Jedlicka et al. · 2021 · American Journal of Pathology
21. Polymersomes as Stable Nanocarriers for a Highly Immunogenic and Durable SARS-CoV-2 Spike Protein Subunit Vaccine
    Jian Hang Lam, Amit Kumar Khan, Thomas Cornell, Teck Wan Chia, Regine J. Dress, Wen Wang William Yeow, Nur Khairiah Mohd-Ismail, Shrinivas Venkataraman, Kim Tien Ng, Yee‐Joo Tan et al. · 2021 · ACS Nano
22. Rotavirus as an Expression Platform of Domains of the SARS-CoV-2 Spike Protein
    Asha A. Philip, J. Patton · 2021 · Vaccines
23. Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates
    M. Joyce, Hannah A. D. King, Ines Elakhal Naouar, Aslaa Ahmed, Kristina K. Peachman, Camila Macedo Cincotta, C. Subra, Rita E. Chen, P. Thomas, Wei-Hung Chen et al. · 2021 · bioRxiv
24. A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian Hamsters
    Anna Claire Fagre, John Manhard, Rachel A Adams, Miles Eckley, Shi-Jun Zhan, Juliette Lewis, Savannah M. Rocha, Catherine M. Woods, Karina Kuo, Wuxiang Liao et al. · 2020 · Frontiers in Immunology
25. Mechanisms of Dysregulated Humoral and Cellular Immunity by SARS-CoV-2
    N. Taefehshokr, Sina Taefehshokr, B. Heit · 2020 · Pathogens
26. An intranasal nanoparticle STING agonist protects against respiratory viruses in animal models
    Ankita Leekha, Arash Saeedi, Monish Kumar, K M Samiur Rahman Sefat, Melisa A. Martinez-Paniagua, Hui Meng, Mohsen Fathi, Rohan SUDHIR Kulkarni, Kate Reichel, Sujit Biswas et al. · 2024 · Nature Communications
27. Enhanced innate immune suppression by SARS-CoV-2 Omicron subvariants BA.4 and BA.5
    Ann-Kathrin Reuschl, Lucy G. Thorne, M. Whelan, Dejan Mesner, Roberta Ragazzini, Giulia Dowgier, Nathasha Bogoda, Jane Turner, Wilhelm Furnon, Vanessa M. Cowton et al. · 2022 · bioRxiv
28. Neutralizing Antibodies and Antibody-Dependent Enhancement in COVID-19: A Perspective
    Swati Ajmeriya, Amit Kumar, Subhradip Karmakar, Shweta Rana, Harpreet Singh · 2022 · Journal of the Indian Institute of Science
29. Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study
    Shelly Karuna, Shuying Sue Li, Shannon Grant, Stephen R. Walsh, Ian Frank, Martín Casapía, Meg Trahey, Ollivier Hyrien, Leigh H. Fisher, Maurine D. Miner et al. · 2021 · PLoS Medicine
30. Longitudinal analysis of SARS-CoV-2 spike and RNA-dependent RNA polymerase protein sequences reveals the emergence and geographic distribution of diverse mutations
    William M. Showers, Sonia M. Leach, Katerina J. Kechris, Michael Strong · 2021 · Infection Genetics and Evolution
31. Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition
    Kevin J. Kramer, N. Johnson, Andrea R. Shiakolas, Naveenchandra Suryadevara, S. Periasamy, Nagarajan Raju, Jazmean K. Williams, D. Wrapp, Seth J. Zost, Lauren M. Walker et al. · 2021 · Cell Reports
32. Comprehensive Deep Mutational Scanning Reveals the Immune-Escaping Hotspots of SARS-CoV-2 Receptor-Binding Domain Targeting Neutralizing Antibodies
    Keng‐Chang Tsai, Yu-Ching Lee, Tien-Sheng Tseng · 2021 · Frontiers in Microbiology
33. Prophylaxis for COVID-19: a systematic review
    Mikaëla Smit, Annalisa Marinosci, Thomas Agoritsas, Alexandra Calmy · 2021 · Clinical Microbiology and Infection
34. Structural Immunology of SARS ‐ CoV ‐2
    Meng Yuan, Ian A. Wilson · 2024 · Immunological Reviews
35. Insights into next generation sequencing guided antibody selection strategies
    M. F. Erasmus, F. Ferrara, S. D'Angelo, Laura Spector, Camila Leal-Lopes, Andre A. R. Teixeira, Jesper Sørensen, Suhani Nagpal, Kathryn Perea-Schmittle, A. Choudhary et al. · 2023 · Scientific Reports
36. Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries
    Tom Z. Yuan, P. Garg, Linya Wang, Jordan R. Willis, Eric Kwan, Ana G. Lujan Hernandez, Emily Tuscano, Emily N Sever, Erica Keane, Cinque S. Soto et al. · 2021 · mAbs
37. Evaluating Humoral Immunity against SARS-CoV-2: Validation of a Plaque-Reduction Neutralization Test and a Multilaboratory Comparison of Conventional and Surrogate Neutralization Assays
    Emelissa J. Valcourt, K. Manguiat, Alyssia Robinson, Yi-Chan Lin, K. Abe, S. Mubareka, A. Shigayeva, Zoe Zhong, Roxie C. Girardin, Alan P. Dupuis et al. · 2021 · Microbiology spectrum
38. Beta RBD boost broadens antibody-mediated protection against SARS-CoV-2 variants in animal models
    Daniel J. Sheward, Marco Mandolesi, Egon Urgard, Changil Kim, Leo Hanke, Laura Perez Vidakovics, Alec P. Pankow, Natalie L. Smith, Xaquín Castro Dopico, Gerald M. McInerney et al. · 2021 · Cell Reports Medicine
39. IgG Antibodies Develop to Spike but Not to the Nucleocapsid Viral Protein in Many Asymptomatic and Light COVID-19 Cases
    M. Tutukina, A. Kaznadzey, M. Kireeva, I. Mazo · 2021 · Viruses
40. SARS-CoV-2 cell entry and targeted antiviral development
    Zi-Nuo Chen, R. Du, Jazmin M. Galván Achi, Li-Jun Rong, Q. Cui · 2021 · Acta Pharmaceutica Sinica B
41. Neutralizing Monoclonal Anti-SARS-CoV-2 Antibodies Isolated from Immunized Rabbits Define Novel Vulnerable Spike-Protein Epitope
    Efi Makdasi, Y. Levy, R. Alcalay, Tal Noy-Porat, E. Zahavy, A. Mechaly, E. Epstein, Eldar Peretz, H. Cohen, L. Bar-On et al. · 2021 · Viruses
42. Current progress and challenges in the design and development of a successful COVID-19 vaccine
    Ting-Ting Li, Tian-Ying Zhang, Ying Gu, Shaowei Li, N. Xia · 2021 · Fundamental Research
43. Evaluation of SARS-CoV-2 neutralization assays for antibody monitoring in natural infection and vaccine trials
    Anton M. Sholukh, A. Fiore-Gartland, E. S. Ford, Y. Hou, Long-Ping V. Tse, F. Lempp, Hannah Kaiser, Russell Saint Germain, Emily L. Bossard, Jin-Kee Jia et al. · 2020 · medRxiv
44. Hijacking Extracellular Targeted Protein Degrader–Drug Conjugates for Enhanced Drug Delivery
    Fang-Zhu Zhao, Yan Wu, K. Schaefer, Yun Zhang, Kun Miao, Zi Yao, Snehal D. Ganjave, Kaan Kumru, Trenton M. Peters-Clarke, Alex Inague et al. · 2025 · Journal of the American Chemical Society
45. Saponin nanoparticle adjuvants incorporating Toll-like receptor agonists drive distinct immune signatures and potent vaccine responses
    Ben S. Ou, Julie Baillet, Maria V. Filsinger Interrante, J. Adamska, Xue-Ting Zhou, Olivia M. Saouaf, Jerry Yan, J. Klich, C. Jons, Emily L. Meany et al. · 2024 · Science Advances
46. Application of recombinant antibodies for treatment of Clostridioides difficile infection: Current status and future perspective
    H. Raeisi, M. Azimirad, Ali Nabavi-Rad, Hamid Asadzadeh Aghdaei, A. Yadegar, M. Zali · 2022 · Frontiers in Immunology
47. Identification of Entry Inhibitors against Delta and Omicron Variants of SARS-CoV-2
    R. K. Lee, Tian-Neng Li, Sui-Yuan Chang, Tai-Ling Chao, Chun-Hsien Kuo, Maxwell Pan, Yu-Ting Chiou, Kuan-Ju Liao, Yi Yang, Yi-Hsuan Wu et al. · 2022 · International Journal of Molecular Sciences
48. The mutational dynamics of the SARS-CoV-2 virus in serial passages in vitro
    S. Sonnleitner, S. Sonnleitner, E. Hinterbichler, H. Halbfurter, Dominik B. C. Kopecky, S. Koblmüller, C. Sturmbauer, W. Posch, G. Walder · 2022 · Virologica Sinica
49. Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants
    Yi-Nan Zhang, Jennifer Paynter, Cindy Sou, Tatiana Fourfouris, Ying Wang, Ciril Abraham, Timothy Ngo, Yi Zhang, Linling He, Jiang Zhu · 2021 · Science Advances
50. Glycosylation and Serological Reactivity of an Expression-enhanced SARS-CoV-2 Viral Spike Mimetic
    H. Chawla, S. Jossi, S. Faustini, Firdaus Samsudin, J. Allen, Y. Watanabe, M. Newby, E. Marcial-Juárez, R. Lamerton, J. McLellan et al. · 2021 · Journal of Molecular Biology
51. An Overview of the Pathogenesis, Transmission, Diagnosis, and Management of Endemic Human Coronaviruses: A Reflection on the Past and Present Episodes and Possible Future Outbreaks
    Adeoye John Kayode, Folasade O. Banji-Onisile, Ademola Olufolahan Olaniran, Anthony Ifeanyi Okoh · 2021 · Pathogens
52. Endogenous Regulation and Pharmacological Modulation of Sepsis-Induced HMGB1 Release and Action: An Updated Review
    Shu Zhu, Wei Wang, Xiaoling Qiang, Weiqiang Chen, Xiqian Lan, Jianhua Li, Haichao Wang · 2021 · Cells
53. Neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independently of symptoms in adults
    A. Wagner, A. Guzek, J. Ruff, J. Jasińska, U. Scheikl, I. Zwazl, M. Kundi, H. Stockinger, Maria R. Farcet, T. Kreil et al. · 2021 · Communications Medicine
54. Recent advances in antibody‐based immunotherapy strategies for COVID‐19
    Abdolreza Esmaeilzadeh, Samaneh Miri Rostami, Pegah Moharrami Yeganeh, Safa Tahmasebi, Majid Ahmadi · 2021 · Journal of Cellular Biochemistry
55. Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses
    Georgia Bullen, J. Galson, G. Hall, Pedro Villar, Lien Moreels, Line Ledsgaard, G. Mattiuzzo, E. Bentley, Edward W. Masters, David M Tang et al. · 2021 · Frontiers in Immunology
56. A longitudinal study of convalescent plasma (CCP) donors and correlation of ABO group, initial neutralizing antibodies (nAb), and body mass index (BMI) with nAb and anti‐nucleocapsid (NP) SARS‐CoV‐2 antibody kinetics: Proposals for better quality of CCP collections
    S. Wendel, R. Fontão-Wendel, R. Fachini, G. Candelaria, P. Scuracchio, R. Achkar, M. Brito, L. F. Reis, A. Camargo, M. Amano et al. · 2021 · Transfusion
57. A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection
    Hejun Liu, M. Yuan, De-Li Huang, S. Bangaru, C. D. Lee, Linghang Peng, Xue-Yong Zhu, D. Nemazee, M. V. van Gils, R. Sanders et al. · 2021 · bioRxiv
58. An integrated technology for quantitative wide mutational scanning of human antibody Fab libraries
    Petersen, Brian M., Kirby, Monica B., Chrispens, Karson M., Irvin, Olivia M., Strawn, Isabell K., Haas, Cyrus M., Walker, Alexis M., Baumer, Zachary T., Ulmer, Sophia A., Ayala, Edgardo et al. · 2024 · Nature Communications
59. An intranasal subunit vaccine induces protective systemic and mucosal antibody immunity against respiratory viruses in mouse models
    A. Anthi, Anette Kolderup, E. B. Vaage, Malin Bern, Sopisa Benjakul, Elias Tjärnhage, Fulgencio Ruso-Julve, Kjell-Rune Jensen, H. E. Lode, M. Vaysburd et al. · 2025 · Nature Communications
60. Multi-omics for COVID-19: driving development of therapeutics and vaccines
    Mengyu Guo, Muya Xiong, Jinying Peng, Tong Guan, Haixia Su, Yanyi Huang, Cai‐Guang Yang, Yang Li, Diana Boraschi, Thanigaimalai Pillaiyar et al. · 2023 · National Science Review
61. COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants
    Daniel Junker, Alex Dulovic, Matthias Becker, Teresa R. Wagner, Philipp D. Kaiser, Bjoern Traenkle, Katharina Kienzle, Stefanie Bunk, Carlotta Struemper, Helene Anna Haeberle et al. · 2022 · Scientific Reports
62. SARS-CoV-2-related pangolin coronavirus exhibits similar infection characteristics to SARS-CoV-2 and direct contact transmissibility in hamsters
    Zhen-Dong Guo, Cheng Zhang, Chunmao Zhang, Huan Cui, Zhaoliang Chen, Xinyun Jiang, Tie-Cheng Wang, Yuan-Guo Li, Jun Liu, Zhonghai Wan et al. · 2022 · iScience
63. Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?
    Jingjing Zhang, Han Zhang, Li-Tao Sun · 2022 · mAbs
64. Uncovering a conserved vulnerability site in SARS‐CoV‐2 by a human antibody
    Ting-Yi Li, H. Cai, Ya-Pei Zhao, Yanfang Li, Y. Lai, H. Yao, Liu Daisy Liu, Zhou Sun, Martje Fentener van Vlissingen, T. Kuiken et al. · 2021 · EMBO Molecular Medicine
65. Phenotypic determinism and stochasticity in antibody repertoires of clonally expanded plasma cells
    D. Neumeier, A. Yermanos, Andreas Agrafiotis, Lucia Csepregi, Tasnia Chowdhury, Roy A. Ehling, Raphael Kuhn, Tudor-Stefan Cotet, Raphaël Brisset-Di Roberto, Mariangela Di Tacchio et al. · 2021 · bioRxiv
66. Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques
    K. V. van Rompay, K. Olstad, R. Sammak, Joseph C. Dutra, Jennifer K. Watanabe, J. Usachenko, Ramya Immareddy, A. Verma, Yashavanth Shaan Lakshmanappa, B. Schmidt et al. · 2021 · PLoS Pathogens
67. Human Immunodeficiency Viruses Pseudotyped with SARS-CoV-2 Spike Proteins Infect a Broad Spectrum of Human Cell Lines through Multiple Entry Mechanisms
    Chuan Xu, Annie Wang, Ke Geng, W. Honnen, Xue-Ning Wang, N. Bruiners, Sukhwinder Singh, F. Ferrara, S. D'Angelo, A. Bradbury et al. · 2021 · Viruses
68. Animal Models of COVID-19 II. Comparative Immunology
    Rebecca T. Veenhuis, Caroline J. Zeiss · 2021 · ILAR Journal
69. The Mechanisms and Animal Models of SARS-CoV-2 Infection
    Wenrui Jia, Juan Wang, Bao Sun, Jiecan Zhou, Yamin Shi, Zheng Zhou · 2021 · Frontiers in Cell and Developmental Biology
70. Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge
    Martin Sebastian Winkler, Tomasz Skirecki, Frank Martin Brunkhorst, Sara Cajander, Jean‐Marc Cavaillon, Ricard Ferrer, Stefanie B. Flohé, Alberto García‐Salido, Evangelos J. Giamarellos‐Bourboulis, Massimo Girardis et al. · 2021 · EBioMedicine
71. Hydrogel-based slow release of a receptor-binding domain subunit vaccine elicits neutralizing antibody responses against SARS-CoV-2
    Emily C. Gale, Abigail E. Powell, Gillie A. Roth, Emily L. Meany, Jerry Yan, Ben S. Ou, Abigail K. Grosskopf, J. Adamska, Vittoria C. T. M. Picece, Andrea I. d'Aquino et al. · 2021 · bioRxiv
72. High-throughput strategies for monoclonal antibody screening: advances and challenges
    Xiaodong Wang, Baoying Ma, Shi-Ying Lai, Xiang-Dong Cai, Yan-Guang Cong, Jun-Fa Xu, Peng-Fei Zhang · 2025 · Journal of Biological Engineering
73. Mutations in S2 subunit of SARS-CoV-2 Omicron spike strongly influence its conformation, fusogenicity, and neutralization sensitivity
    Sahil Kumar, Rathina Delipan, Debajyoti Chakraborty, Kawkab Kanjo, Randhir Singh, Nittu Singh, Samreen Siddiqui, Akansha Tyagi, Vinitaa Jha, Krishan Gopal Thakur et al. · 2023 · Journal of Virology
74. Subcutaneous delivery of an antibody against SARS-CoV-2 from a supramolecular hydrogel depot
    Catherine M. Kasse, Anthony C. Yu, Abigail E. Powell, Gillie A. Roth, Celine S. Liong, C. Jons, Awua Buahin, Caitlin L. Maikawa, Xueting Zhou, S. Youssef et al. · 2023 · Biomaterials Science
75. Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitors
    Payton A. B. Weidenbacher, Eric Waltari, Izumi de los Rios Kobara, Benjamin N. Bell, Mary Kate Morris, Ya-Chen Cheng, Carl Veith Hanson, John E. Pak, Peter S. Kim · 2022 · Nature Chemical Biology
76. Next-Generation Serology by Mass Spectrometry: Readout of the SARS-CoV-2 Antibody Repertoire
    Rafael Donadelli Melani, Benjamin J. Des Soye, Jared O. Kafader, Eleonora Forte, Michael A. R. Hollas, Voislav Blagojevic, Fernanda Negrão, John P. McGee, Bryon Drown, Cameron Lloyd-Jones et al. · 2021 · Journal of Proteome Research
77. Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics
    Shaojuan Zhao, Hua-Jun Zhang, Xing-Lou Yang, Hai-Wei Zhang, Ying Chen, Yan-Cheng Zhan, Xiaoqing Zhang, Ren-Di Jiang, Mei-Qin Liu, Lan Liu et al. · 2021 · Nature Communications
78. Unleashing the potential of cell membrane-based nanoparticles for COVID-19 treatment and vaccination
    Miguel Pereira-Silva, Gaurav Chauhan, Matthew D. Shin, Clare Hoskins, M. Madou, S. Martínez-Chapa, N. Steinmetz, F. Veiga, A. C. Paiva-Santos · 2021 · Expert Opinion on Drug Delivery
79. Intermolecular Interaction Analyses on SARS-CoV-2 Spike Protein Receptor Binding Domain and Human Angiotensin-Converting Enzyme 2 Receptor-Blocking Antibody/Peptide Using Fragment Molecular Orbital Calculation
    Kazuki Watanabe, Chiduru Watanabe, T. Honma, Yu-Shi Tian, Y. Kawashima, N. Kawashita, T. Takagi, Kaori Fukuzawa · 2021 · Journal of Physical Chemistry Letters
80. Vaccination boosts protective responses and counters SARS-CoV-2-induced pathogenic memory B cells
    P. Mishra, N. Bruiners, Rahul Ukey, Pratik Datta, A. Onyuka, D. Handler, Sabiha M. Hussain, W. Honnen, Sukhwinder Singh, V. Guerrini et al. · 2021 · medRxiv
81. Membrane lectins enhance SARS-CoV-2 infection and influence the neutralizing activity of different classes of antibodies
    F. Lempp, Leah B. Soriaga, Martin Montiel-Ruiz, F. Benigni, Julia Noack, Young-Jun Park, S. Bianchi, A. Walls, J. Bowen, Jia-Yi Zhou et al. · 2021 · bioRxiv
82. Drug discovery and development targeting the life cycle of SARS-CoV-2
    H. Su, Yechun Xu, Hua-Liang Jiang · 2021 · Fundamental Research
83. A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants
    Shan, Sisi, Mok, Chee Keng, Zhang, Shuyuan, Lan, Jun, Li, Jizhou, Yang, Ziqing, Wang, Ruoke, Cheng, Lin, Fang, Mengqi, Aw, Zhen Qin et al. · 2021 · Frontiers in Immunology
84. Attenuated humoral responses in HIV after SARS-CoV-2 vaccination linked to B cell defects and altered immune profiles
    E. Touizer, Aljawharah Alrubayyi, R. Ford, N. Hussain, P. Gerber, Hiu-Long Shum, C. Rees-Spear, L. Muir, E. Gea-Mallorquí, J. Kopycinski et al. · 2022 · iScience
85. SARS-CoV-2 reactive and neutralizing antibodies discovered by single-cell sequencing of plasma cells and mammalian display
    Roy A. Ehling, Cédric R. Weber, Derek M. Mason, Simon Friedensohn, Bastian Wagner, Florian Bieberich, Edo Kapetanovic, Rodrigo Vazquez-Lombardi, Raphaël B. Di Roberto, Kai-Lin Hong et al. · 2021 · Cell Reports
86. Potent Molecular Feature-based Neutralizing Monoclonal Antibodies as Promising Therapeutics Against SARS-CoV-2 Infection
    Arnaud John Kombe Kombe, Ayesha Zahid, Ahmed Mohammed, Ronghua Shi, Tengchuan Jin · 2021 · Frontiers in Molecular Biosciences
87. Comprehensive mapping of neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination
    Xin-Hua Chen, Zhi-Yuan Chen, A. Azman, Rui Sun, Wan-Ying Lu, N. Zheng, Jia-Xin Zhou, Qian-Hui Wu, Xiao-Wei Deng, Ze-Yao Zhao et al. · 2021 · medRxiv
88. Comparison of Antibody Class-Specific SARS-CoV-2 Serologies for the Diagnosis of Acute COVID-19
    H. Verkerke, M. Horwath, B. Saeedi, D. Boyer, J. W. Allen, J. Owens, C. Arthur, H. Nakahara, Jennifer Rha, K. Patel et al. · 2021 · Journal of Clinical Microbiology
89. Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination
    Yuxin Chen, Liguo Zhu, Weijin Huang, Xin Tong, Hai Wu, Yue Tao, Bei Tong, Haibin Huang, Jiachen Chen, Xiang‐An Zhao et al. · 2021 · Emerging Microbes & Infections
90. The smallest functional antibody fragment: Ultralong CDR H3 antibody knob regions potently neutralize SARS-CoV-2
    Ruiqi Huang, Gabrielle Warner Jenkins, Yunjeong Kim, R. Stanfield, Amrinder Singh, M. Martinez-Yamout, G. Kroon, J. Torres, A. Jackson, A. Kelley et al. · 2023 · Proceedings of the National Academy of Sciences of the United States of America
91. A plant-produced SARS-CoV-2 spike protein elicits heterologous immunity in hamsters
    Emmanuel Margolin, Georgia Schäfer, J. Allen, S. Gers, J. Woodward, Andrew D. Sutherland, Melissa J. Blumenthal, A. Meyers, M. Shaw, W. Preiser et al. · 2023 · Frontiers in Plant Science
92. ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants
    Jeffrey Seow, Carl Graham, Sadie R. Hallett, Thomas Lechmere, Thomas J. A. Maguire, Isabella Huettner, Daniel Cox, Hataf Khan, Suzanne Pickering, Rebekah Roberts et al. · 2022 · Cell Reports
93. Reduced Serological Response to COVID-19 Vaccines in Patients with IBD is Further Diminished by TNF Inhibitor Therapy; Early Results of the VARIATION study [VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON]
    Jayne Doherty, Neil O Morain, Róisín Stack, Parker Girod, Miriam Tosetto, Rosanna Inzitiari, Juliette Sheridan, Garret J. Cullen, Edel McDermott, Maire Buckley et al. · 2022 · Journal of Crohn s and Colitis
94. Conserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike Proteins
    Zi-Jun Wang, Frauke Muecksch, Alice Cho, C. Gaebler, H. Hoffmann, Victor A. Ramos, Shuaizhou Zong, M. Cipolla, Bryant Johnson, Fabian Schmidt et al. · 2022 · bioRxiv
95. A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques
    Ronald R. Cobb, Joseph P. Nkolola, P. Gilchuk, A. Chandrashekar, Jing-You Yu, R. House, C. Earnhart, N. Dorsey, S. Hopkins, Doris M. Snow et al. · 2022 · i Medicina
96. High‐resolution analysis of individual spike peptide‐specific CD4 + T‐cell responses in vaccine recipients and COVID‐19 patients
    Hendrik Karsten, Leon Cords, Tim Westphal, M. Knapp, T. Brehm, L. Hermanussen, T. Omansen, S. Schmiedel, R. Woost, V. Ditt et al. · 2022 · Clinical & Translational Immunology
97. An overview of methods for the structural and functional mapping of epitopes recognized by anti-SARS-CoV-2 antibodies
    I. Francino-Urdaniz, T. Whitehead · 2021 · RSC Chemical Biology
98. Dromedary camels as a natural source of neutralizing nanobodies against SARS-CoV-2
    L. Chouchane, J. Grivel, E. Farag, Igor Pavlovski, Selma Maacha, Abbirami Sathappan, H. Al-Romaihi, Sirin W. J. Abuaqel, Manar Ata, A. Chouchane et al. · 2021 · JCI Insight
99. USP2 inhibition prevents infection with ACE2-dependent coronaviruses in vitro and is protective against SARS-CoV-2 in mice
    Fabin Dang, Lei Bai, Jiazhen Dong, Xiaoping Hu, Jingchao Wang, João A. Paulo, Yan Xiong, Xiaowei Liang, Yishuang Sun, Yuncai Chen et al. · 2023 · Science Translational Medicine
100. Memory B cell development elicited by mRNA booster vaccinations in the elderly
     Zijun Wang, Frauke Muecksch, Raphael Raspe, Frederik Johannsen, Martina Turroja, Marie Canis, Mohamed A. ElTanbouly, Gabriela S. Silva Santos, Brianna Johnson, Viren A. Baharani et al. · 2023 · The Journal of Experimental Medicine